National Research Corp Stock Buy Hold or Sell Recommendation
| NRC Stock | USD 19.48 0.06 0.31% |
Considering the 90-day investment horizon and complete risk avoidance on your part, our recommendation regarding National Research Corp is 'Strong Sell'. Macroaxis provides National Research buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NRC positions.
Check out National Research Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as National and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards National Research Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
National |
Execute National Research Buy or Sell Advice
The National recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on National Research Corp. Macroaxis does not own or have any residual interests in National Research Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute National Research's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
National Research Trading Alerts and Improvement Suggestions
| National Research generated a negative expected return over the last 90 days | |
| National Research has a frail financial position based on the latest SEC disclosures | |
| About 37.0% of the company outstanding shares are owned by corporate insiders | |
| On 11th of October 2024 National Research paid $ 0.12 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: National Research Will Want To Turn Around Its Return Trends |
National Research Returns Distribution Density
The distribution of National Research's historical returns is an attempt to chart the uncertainty of National Research's future price movements. The chart of the probability distribution of National Research daily returns describes the distribution of returns around its average expected value. We use National Research Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of National Research returns is essential to provide solid investment advice for National Research.
| Mean Return | -0.15 | Value At Risk | -4.72 | Potential Upside | 3.79 | Standard Deviation | 2.57 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of National Research historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
National Stock Institutional Investors
| Shares | Millennium Management Llc | 2024-06-30 | 214.9 K | Wells Fargo & Co | 2024-06-30 | 179.1 K | Hotchkis & Wiley Capital Management Llc | 2024-09-30 | 138.2 K | Northwest & Ethical Investments L.p. | 2024-09-30 | 129.2 K | Eagle Asset Management, Inc. | 2024-06-30 | 124.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 123.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 123.3 K | Bank Of America Corp | 2024-06-30 | 120.9 K | Comerica Bank | 2024-09-30 | 99.8 K | Kayne Anderson Rudnick Investment Management Llc | 2024-06-30 | 3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.8 M |
National Research Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 526K | 21.2M | 19.7M | (29.3M) | (18.4M) | (17.5M) | |
| Free Cash Flow | 36.3M | 36.7M | 40.8M | 26.4M | 22.3M | 16.1M | |
| Depreciation | 5.5M | 7.5M | 6.4M | 5.3M | 5.9M | 3.7M | |
| Other Non Cash Items | (6K) | (248K) | 7K | 3.1M | 8K | 7.6K | |
| Dividends Paid | 31.3M | 10.5M | 9.2M | 21.0M | (36.4M) | (34.5M) | |
| Capital Expenditures | 4.7M | 4.0M | 5.5M | 9.8M | 15.8M | 16.6M | |
| Net Income | 32.4M | 37.3M | 37.5M | 31.8M | 31.0M | 32.5M | |
| End Period Cash Flow | 13.5M | 34.7M | 54.4M | 25.0M | 6.7M | 6.3M | |
| Change To Inventory | 277K | 543K | (1.1M) | (1.0) | (0.9) | (0.85) | |
| Change Receivables | 311K | (2.3M) | 343K | (733K) | (659.7K) | (626.7K) | |
| Net Borrowings | (3.7M) | (3.6M) | (4.1M) | (4.4M) | (5.1M) | (4.8M) | |
| Change To Netincome | 2.4M | 743K | 663K | (30K) | (27K) | (25.7K) | |
| Investments | (4.7M) | (3.7M) | (8.5M) | (9.8M) | (14.0M) | (13.3M) |
National Research Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to National Research or Health Care Providers & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that National Research's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a National stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.36 | |
β | Beta against Dow Jones | 1.75 | |
σ | Overall volatility | 2.59 | |
Ir | Information ratio | -0.11 |
National Research Volatility Alert
National Research Corp exhibits very low volatility with skewness of 0.03 and kurtosis of 0.7. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure National Research's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact National Research's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.National Research Fundamentals Vs Peers
Comparing National Research's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze National Research's direct or indirect competition across all of the common fundamentals between National Research and the related equities. This way, we can detect undervalued stocks with similar characteristics as National Research or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of National Research's fundamental indicators could also be used in its relative valuation, which is a method of valuing National Research by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare National Research to competition |
| Fundamentals | National Research | Peer Average |
| Return On Equity | 0.59 | -0.31 |
| Return On Asset | 0.19 | -0.14 |
| Profit Margin | 0.19 % | (1.27) % |
| Operating Margin | 0.22 % | (5.51) % |
| Current Valuation | 507.48 M | 16.62 B |
| Shares Outstanding | 23.48 M | 571.82 M |
| Shares Owned By Insiders | 37.30 % | 10.09 % |
| Shares Owned By Institutions | 52.08 % | 39.21 % |
| Number Of Shares Shorted | 343.79 K | 4.71 M |
| Price To Earning | 26.72 X | 28.72 X |
| Price To Book | 13.21 X | 9.51 X |
| Price To Sales | 3.17 X | 11.42 X |
| Revenue | 148.58 M | 9.43 B |
| Gross Profit | 94.52 M | 27.38 B |
| EBITDA | 45.98 M | 3.9 B |
| Net Income | 30.97 M | 570.98 M |
| Cash And Equivalents | 32.97 M | 2.7 B |
| Cash Per Share | 1.33 X | 5.01 X |
| Total Debt | 38.96 M | 5.32 B |
| Debt To Equity | 0.37 % | 48.70 % |
| Current Ratio | 1.31 X | 2.16 X |
| Book Value Per Share | 1.48 X | 1.93 K |
| Cash Flow From Operations | 38.11 M | 971.22 M |
| Short Ratio | 4.37 X | 4.00 X |
| Earnings Per Share | 1.12 X | 3.12 X |
| Price To Earnings To Growth | 3.42 X | 4.89 X |
| Number Of Employees | 435 | 18.84 K |
| Beta | 0.53 | -0.15 |
| Market Capitalization | 457.31 M | 19.03 B |
| Total Asset | 122.44 M | 29.47 B |
| Retained Earnings | (30.53 M) | 9.33 B |
| Working Capital | (11.84 M) | 1.48 B |
| Current Asset | 27.6 M | 9.34 B |
Note: Acquisition by Karas Kevin R of 10981 shares of National Research subject to Rule 16b-3 [view details]
National Research Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as National . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About National Research Buy or Sell Advice
When is the right time to buy or sell National Research Corp? Buying financial instruments such as National Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having National Research in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
| View All Next | Launch |
Check out National Research Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of National Research. If investors know National will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about National Research listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.25) | Dividend Share 0.48 | Earnings Share 1.12 | Revenue Per Share 6.013 | Quarterly Revenue Growth (0.06) |
The market value of National Research Corp is measured differently than its book value, which is the value of National that is recorded on the company's balance sheet. Investors also form their own opinion of National Research's value that differs from its market value or its book value, called intrinsic value, which is National Research's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because National Research's market value can be influenced by many factors that don't directly affect National Research's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between National Research's value and its price as these two are different measures arrived at by different means. Investors typically determine if National Research is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, National Research's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.